NCT03631420招募中1 期
The Safety and Feasibility of UMC119-01 Cell Therapy in Infants at High Risk for Bronchopulmonary Dysplasia
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 9
- 试验地点
- 1
- 主要终点
- The incidence and frequency of adverse events related to administration of UMC119-01.
研究概览
简要总结
The clinical study with UMC119-01 is designed to investigate the safety in patients with bronchopulmonary dysplasia ("BPD"). This will be a dose escalation, open-label, single-center study in infants at high risk for BPD.
详细描述
UMC119-01 is ex vivo cultured human umbilical cord tissue-derived mensenchymal stem cells product which is intended for prevention of Bronchopulmonary dysplasia.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 3 Days 至 51 Days（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Neonatal infants who fulfil all of the following criteria will be enrolled:
- •Subjects of postnatal age between 3 to 30 days.
- •Are male and female infants born at GA between 23 weeks to 29 weeks. The postmenstrual age of subject received UMC119-01 should be no more than PMA36 weeks.
- •Subjects with birth weight between 501g to 1249 g.
- •Have endotracheal tube in place as part of SoC for preterm infants with BPD at screening and on treatment visit (Day 0), and that they will have not been intubated for the purposes of this study.
- •A subject who is intubated and receiving mechanical ventilation with a fraction of inspired oxygen (FiO2) of 0.25 or greater at Screening.
- •A subject who has had either a deterioration or no change in the setting of mechanical ventilation within the 24 hours before trial enrollment.
- •Written informed consent has been provided by the subject's parents, legal guardians, or a legal representative, who agree to comply with all of the study procedures, including those in the long-term safety surveillance period.
排除标准
- •Neonatal infants who meet any of the following criteria will be excluded:
- •Have a major congenital abnormality, including neurological (including anencephaly and similar malformations), hepatic, renal, cardiovascular abnormality (except for patent ductus arteriosus, PDA).
- •Have a known genetic syndrome.
- •Have a condition that makes them ineligible for participation in this study, as determined by the investigator.
- •Have C-reactive protein (CRP) >30 mg/L; or any infections including pneumonia, sepsis, or shock.
- •Have pre-existing severe intraventricular hemorrhage (IVH) (grade ≥3).
- •Have active pulmonary hemorrhage or air leak syndrome.
- •Have abnormal hepatic (AST, ALT >150 U/L or direct bilirubin >2 mg/dL or total bilirubin >15 mg/dL) or renal function (serum creatinine >1 mg/dL or oliguria).
- •Are known to be infected with HIV or CMV.
- •Are expected to have surgery within 24 hours prior to and/or after UMC119 01 instillation.
- •Are expected to receive any other intratracheal treatments, including surfactant within 72 hours prior to and/or after UMC119 01 instillation.
- •Are currently participating in any other interventional clinical trial.
结局指标
主要结局
The incidence and frequency of adverse events related to administration of UMC119-01.
时间窗: 3 months from the day of administration
• The incidence and frequency of adverse events (AEs) and serious adverse events (SAEs), including their relationship to the administration of UMC119 01.
次要结局
- Changes of inflammatory markers (pg/ml) before and after administration.(3 days and 7 days after administration)
- Incidence of moderate/severe BPD or death at 36 weeks postmenstrual age (PMA).(36 weeks postmenstrual age (PMA))
- The percentage of subjects who died from any cause during the study.(3 months from the day of administration)
- Changes of the oxygen saturation.(3 months from the day of administration)
- The number of days of intubation, or where ventilator or oxygen therapy.(3 months from the day of administration)
- Changes of chest x-ray findings in participants before and after administration.(3 months from the day of administration)
- Comparison of the incidence and severity of preterm children's complications in participants before and after administration.(3 months from the day of administration)
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
1 期
Mesenchymal Stem Cells for The Treatment of Chronic Obstructive Pulmonary DiseaseChronic Obstructive Pulmonary Disease ModerateNCT04206007Meridigen Biotech Co., Ltd.9
Unknown
1 期
Safety and Feasibility Study of Umbilical Cord Blood Mononuclear Cells Transplant to Treat Ischemic StrokeIschemic StrokeBrain IschemiaStrokeNCT01673932China Spinal Cord Injury Network12
Unknown
1 期
Umbilical Cord Blood Mononuclear Cells Therapy in Liver CirrhosisLiver CirrhosisNCT01942915Hebei Medical University10
已完成
不适用
Safety and Performance of UCon for the Treatment of the Symptoms of Overactive Bladder (OAB) / Bowel Dysfunction (BD)Urinary IncontinenceUrge IncontinenceNocturiaUrinary Frequency More Than Once at NightBowel Disorders FunctionalUrinary Incontinence, UrgeIncontinence, Nighttime UrinaryFecal IncontinenceNCT05368246InnoCon Medical80
尚未招募
不适用
Efficacy and Safety of BAI Combined With DEB-BACE of EqualSpheres in the Treatment of Advanced NSCLCCarcinoma, Non-Small Cell LungNCT06127329Gang Wu70